Pharma R&D Portfolio Growth Gap: Commit Immediately to Investment or Acquisition, or Build a Reversible Portfolio Comparison First?
Current product policyLast updated August 25, 2026
Minerva judgment
Recommend first building a time-bound, reversible portfolio comparison that specifies success probabilities, capital requirements, time distributions, and worst-case branches for each path (internal R&D, increased marketing, acquisition) before deciding. This is because a common baseline is currently missing (F4) and downside information is incomplete (F3, U1, U2), making a rushed commitment an irreversible risk (F5).
Decision owner in the teaching simulationChair of the Strategy and Investment Committee, in an independent teaching simulation
Human-controlled next action
The committee chair directs the finance, marketing, and business development teams to build, within a set deadline, a common comparison baseline for internal R&D, marketing, and acquisition (including probabilities, capital, timing, and worst-case branches), to be put to a vote at the next committee meeting.
What would reverse the recommendation
If evidence emerges that: (1) the deterioration rate of drug pricing and return pressures described in F2 has reached a point where the opportunity cost of delaying the comparison exceeds the downside risk shown in U2, or (2) time-bound information appears indicating a specific acquisition target is about to be taken by a competitor, then the committee should reassess whether to launch investment or acquisition immediately rather than wait for the full portfolio comparison. However, this timing and opportunity-cost threshold is not currently specified in the source (U3) and must be defined separately by the committee.
13 · Analysis Group
Watch the actual operation film
Pharma R&D Portfolio Growth Gap: Commit Immediately to Investment or Acquisition, or Build a Reversible Portfolio Comparison First?
The Decision Room interface, case analysis, narration, captions and transcript are in English. The linked official source remains in its original language.
Evidence and endorsement boundary：Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.
Inspect the evidence, then test your own decision context.